Polecompetitivite

DGCIS_CMJN_bleu

Ubifrance-logo
France-logo

Request Meetings with French Companies

Profiles of attending companies are listed below. PLEASE CHECK THIS WEBSITE REGULARLY FOR AN UPDATED LIST.

The DEADLINE to submit your meeting requests is October, 5th.

THE PROCESS:

  1. You will receive a confirmation email for each request made
  2. UBIFRANCE will begin processing all meeting requests from October,5th 2012, and will confirm mutual interest from the other party
  3. A provisional schedule will be sent to you a few days before the event and a finalized schedule on the day of the event

If you have any questions about this process, please CONTACT US.

In order to improve your chances of meeting with the companies of your choice, make your meeting requests as specific, simple and direct as possible. Include information about what your company can offer and what your company is looking for.



Thumb_1347355301_logo-affilogic-single-compressed-jpg

AFFILOGIC

visit website request a meeting with this company
Custom generation of affinity ligands for diagnostics, bioprocessing, research and drug discovery.
More ?
COMPANY :
Affilogic is a biotech company developing a new class of proprietary affinity ligands, Nanofitins®, which constitute a robust and affordable alternative to antibodies. - High affinity (down to 0.1 nM as monomers), - Excellent druggability (very stable & highly soluble), - Better tissue penetration (20 x smaller than mAbs), - Cost effective scale up (cheaper manufacturing process)… Nanofitins® are able to selectively bind a wide range of targets and have proven excellent tools for: - Detection (immunoassays, Western Blot), - Capture (affinity chromatography, protein removal), - Targeting (immunolocalization, in vivo neutralization). Find us on Linked in http://www.linkedin.com/company/1037071 Join the All about Nanofitins® group http://www.linkedin.com/groups?gid=446705
TECHNOLOGY :
The rationale behind Nanofitin® therapeutic projects is to overcome antibodies limitations, in particular by allowing better tissue penetration and patient-friendly formulations of targeted therapeutics. Affilogic invests primarily in the following fields, with partnering available on some programs: Inflammation Nanofitins® are particularly well-suited for a neutralizing mode of action with a binding designed so as to impair ligand/receptor interaction. Inflammatory cascades are thus a target of choice for therapeutic intervention. Neurology Affilogic has designed Nanofitins® that specifically bind to receptors known to actively transport the ligand through the BBB. Nanofitins® in fusion with peptides, proteins or antibodies can act as a vector for CNS addressing, with their small size being of very little impact with the activity of the compound.
OBJECTIVES :
Affilogic is looking for partners for custom generation of Nanofitins® as affinity ligands, co-development of affinity applications and early-stage drug development.
COMPANY INFORMATION :

Close
Thumb_1347376108_alsace-biovalley_logo_bd-mailing-petit-jpg

Alsace BioValley

visit website request a meeting with this company
As a French cluster dedicated to life sciences and healthcare, Alsace BioValley represents an ideal gateway to develop any bio-business on a European scale in an efficient and swift manner. More ?
More ?
COMPANY :
Located in Alsace (France), at the heart of Europe, its environment ensures a background particularly favourable to life sciences and healthcare. Evidence is given with the on-site presence of experts of worldwide repute, multiple platforms offering scientific services, and a lively network including 400 businesses, 60 research laboratories and 20 000 live forces. Its main mission is to federate all players – companies, research laboratories, universities – involved in life sciences & healthcare. Alsace BioValley deploys its actions along 3 main lines :- increasing the competitiveness of local life sciences & healthcare companies through a series of specialised services like commercial representation of companies at international trade fairs, search for partners and / or technologies, support in getting established ...- increasing Alsace attractivity while structuring its territory : specialised real estate, platforms offering specialised scientific services, logistics, pooled services ...- reinforcing and developing its international positioning through development of inter-clusters partnerships, exploratory missions ... Alsace BioValley is also the French representative of BioValley, the trinational cluster involved in life sciences which sweeps away the boundaries of France, Germany and Switzerland – a genuine force serving a successful opening towards Europe and the world.
TECHNOLOGY :
Alsace BioValley spans 2 main domains : - Biopharmaceuticals: from chemistry and genes towards new drugs - Medical technologies: medical and surgical devices, imaging and robotics
OBJECTIVES :
Alsace BioValley is your ideal partner for an easy access to: Licensing opportunities; R&D collaborations and projects funding; Innovative technological platforms; Competitive CRO and CMO; Establishment of European subsidiaries. In addition to that, we are looking to develop strategic partnerships with clusters in the US in order to foster collaboration amongst our companies and counterparts.
COMPANY INFORMATION :

Close
Thumb_1347375652_logo-cynbiose-png

CYNBIOSE

visit website request a meeting with this company
Operating in state-of-the art facilities, Cynbiose conducts ad-hoc exploratory and preclinical studies and development of Primate models in main therapeutic areas.
More ?
COMPANY :
Cynbiose is one of the sole platform in Europe to offer exclusively non human primate (NHP) models for use by private and public companies involved in biomedical research and drug discovery and development activities. Cynbiose offers a large selection of exploratory and preclinical studies organized around a technically highly qualified and controlled platform which meets all regulatory, health, ethical and economic requirements. Cynbiose has developed a wide range of “off the shelf” services and models. Cynbiose is also developing new models in collaboration with clients to better meet the needs of a scientific program or the development of a candidate drug. Cynbiose is fully experienced in all aspects of animal management: import, quarantine, housing, ethical, sanitary, technical and veterinary aspects. Consequently, Cynbiose has obtained the approval of the French authorities for the housing of the different species of NHP used in biomedical research. Cynbiose is a small company (created in 2008) that develops around : -a multi-disciplinary skilled team-including : animal care technicians and veterinarians with great expertise in animal care and animal welfare (AAALAC accreditation in progress), quality auditor to implement quality assurance (GLP accreditation obtained in 2011), study directors assigned to conduct the different phases of sponsored studies and PhD students to develop research programs, -strategic partners as : Bioprim, the only private company in France dedicated to the import and quarantine of NHP for research with health checks and protection of animal welfare, the VetAgro Sup animal test facilities platform (National Veterinary School of Lyon): for animals housing, expertise in all areas of veterinary work, clinical pathology, immunology, endocrinology, histology, surgery and imaging.
TECHNOLOGY :
Services : Operating in state-of-the art facilities, Cynbiose conducts Ad-hoc exploratory and preclinical studies with quality and compliance: Development of NHP models in immunology, CNS, infectious and metabolic diseases for drug efficacy testing and exploratory studies coupled with the use of non-invasive imaging technologies. Species: cynomolgus and rhesus macaques, marmoset, vervet, squirrel monkey. Exploratory studies: pharmacokinetics, PK-PD, toxicokinetics, biodistribution, immunization -all routes of administration, treatment regimen and schedule, all kinds of sponsor formulations -all types of biological sample collection -all types of surgery, biopsy and implants. Study design and roll-out including clinical observation, clinical examination, imaging, gross pathology, clinical biology and immunology, immunomonitoring and bioanalysis Data management and statistical analysis included in a final audited report Privileged access to companion technology platforms on-site: -Voxcan: a CRO specializing in 3D medical imaging services for preclinical studies providing X-Ray scans, molecular and optical tomography. -Platine Pharma Services: a CRO specializing in immunomonitoring of clinical and preclinical phases Access to biosafety level 2 (3 ongoing through the BIOASTER project) facilities to study infectious diseases and conduct challenge studies of the efficacy of anti-infective medicines (drugs and vaccines) and to test genetically modified products. Research programs All these programs are developed in active partnership with academic laboratories and/or private companies, supported by grants and the delivery of excellent science (please ask for our list of peer-reviewed publications) -Metabolic diseases: *NHP model for the preclinical assessment of osteoarthritis and osteoporosis candidate drugs. -Pharmacology of the CNS: *Experimental platform to assess the crossing of the blood-brain barrier using a microdialysis method. -Cardiovascular diseases: *a minimally-invasive closed-chest myocardial occlusion-reperfusion model in rhesus monkeys and *a chronic post ischaemic heart failure model in cynomolgus monkeys - monitoring by means of contrast-enhanced ultrasound imaging. -Infectious diseases: *A primate model for the preclinical assessment of candidate drugs against Plasmodium falciparum and Plasmodium vivax which are responsible for malaria in humans. *Testing of immunostimulant drugs with a broad spectrum of antiviral activity. -NHP models for age-related disorders, epilepsy and inflammation (multiple sclerosis, atherosclerosis…) are under development.
OBJECTIVES :
-give informations on Cynbiose, a small european highly innovative company delivering services using a specific model reliable for drug developement -offer our services focused on the use of NHP models and identify new business opportunities (both for American and French companies) -meet new partners interested in access to NHP models for their programs that could lead to grants research -identify « scientific needs » of the companies that could lead to start development or co-development of new NHP models (implying future privileged access to the model for the companies involved).
COMPANY INFORMATION :

Close
Thumb_1347962466_logo-eyebrain-rvb-h540xl800-png

EyeBrain

visit website request a meeting with this company
EyeBrain develops and manufactures medical devices for the early diagnosis and follow up of neurological and psychiatric diseases.
More ?
COMPANY :
EyeBrain develops and manufactures medical devices for the early diagnosis and follow up of neurological and psychiatric diseases. EyeBrain tools are based on oculomotricity, an objective and finely quantified marker of brain functions. The recording and analysis of eye movements using sophisticated proprietary algorithms allows the testing of specific areas of the brain. The speed and accuracy of EyeBrain technology is a true breakthrough in the diagnosis of neurological disease. The company’s lead product, the Eye Brain Tracker (EBT), has been available since mid-2010. EBT is the first device of its kind to have obtained CE marking. Used as part of normal clinical routine, the EBT can provide valuable help in early characterization of the Parkinson-plus diseases or monitoring the evolution of multiple sclerosis. Its turnover has doubled between 2010 and 2011. The company has received ISO 9001 certification and the oculomotricity examination is reimbursed by French social security.
TECHNOLOGY :
The Eye Brain Tracker (EBT) medical device involves a complete operational package including an eye-tracker, a chinrest, a computer and two screens plus the software needed for stimulation and analysis. The whole operation takes around 15 minutes, from the calibration of the device and the examination itself to the analysis of the results and the edition of a report with norms. This is a binocular device and utilizes an acquisition frequency of 300 hertz, which enables it to obtain a detailed trace. EyeBrain has developed two sophisticated algorithms, one to recognize the pupil and the other to analyze eye movements. This device can be used to diagnose and follow up several pathologies, such as Parkinson-plus syndromes and multiple sclerosis, and analyze reading in dyslexic children. Other pathologies are being studied
OBJECTIVES :
We are looking for distributors in the US. We can also propose our product in clinical studies to evaluate pathologies and impact of drugs.
COMPANY INFORMATION :

Close
Thumb_1347374453_logo_histalim-jpg

HISTALIM

visit website request a meeting with this company
Histalim is a technical platform for histology, cytology and molecular biology offers laboratory services
More ?
COMPANY :
HISTALIM offers technical facilities for histology, cytology and molecular biology that combine: • The stringency of a quality management system in compliance with the most demanding standards of reference (GLP, ISO17025, …) • The Integration of innovative techniques inspired by other disciplines Thanks to the combination of immunochemistry, in situ hybridation, slide digitalization and images analysis, HISTALIM provides accurate quantitative tissues biomarkers for both preclinical and clinical studies. The company can perform analytical and research services in the field of Oncology, Toxicology, Metabolic disease, Dermatology and Neurosciences.
TECHNOLOGY :
- High content screening of tissues biomarkers - Quantitative immunohistochemistry analysis - Cross reactivity of study model - Tailor made morphometric biomarkers - RNA targeting with in situ hybridization - Multicentric clinical analysis thanks to digital pathology - RNA / DNA extraction from FFPE (formolin fixed paraffin embedding) tissues
OBJECTIVES :
We are looking for subcontracting, business partnership with CRO, and research project to develop news histological biomarkers
COMPANY INFORMATION :
  • Address :
      Le Millénaire 126 rue emile baudot - 34000 Montpellier - FRANCE
  • Website :
     http://www.histalim.com

Close
Thumb_1347467756_log-medicen-angl-jpg

Medicen Paris Region

visit website request a meeting with this company
The cluster for innovative therapies and advanced technologies in healthcare of the Paris Region
More ?
COMPANY :
Medicen Paris Region brings together all key life science and healthcare players in the Paris metropolitan area: over 170 small businesses and start-ups, 12 large multinational companies, 9 universities, reknown Research Institutes such as Institut Curie and Institut Pasteur and Europe's largest hospital corporation (38 research hospitals within the same metropolitan area). Medicen Paris Region strategy: - Facilitate access to innovation - Increase innovation transfer from the research stage to industrial products and processes by promoting dynamic networking between SMEs, large companies, academic labs, clinical centers and teaching & training centers - Accelerate time to market of therapeutic and/or technological innovations beneficial to patients Three main R&D areas - Translational medicine - Biological tools for industrial use and biotherapeutic products, - ICT-biology interface: bioinformatics, integrated biology, modeling, e-health and the brain machine interface technology Three major disease areas with unmet diagnostic and therapeutic needs … - Cancer, - Neurodegenerative, sensory and psychiatric diseases, - Infectious diseases Two arising areas - Cardiometabolism - Rare diseases A key objective of Medicen Paris Region’s is to catalyze the emergence of scientifically, technically and economically validated collaborative R&D projects between public and private-sector partners. Project accreditation by the cluster opens the door to several attractive or additional sources of public funding (for companies established in France). Since 2005, 195 R&D projects have been funded by the French Government and local authorities. Medicen has enabled: 14 product arrivals into the market, 6 new industrial processes, 48 patents and 174 peer reviewed international publications
OBJECTIVES :
We are looking for: - Partnering opportunities with cluster like organisations - Partnering opportunities for our member companies (over 170 small businesses and start-ups) - Investors for our member companies
COMPANY INFORMATION :

Close
Thumb_1347291800_medincell_logo-copy-jpg

MEDINCELL

visit website request a meeting with this company
Medincell is a leading biopharmaceutical company that offers innovative technologies in Drug Delivery.
More ?
COMPANY :
Medincell core business consists in designing long acting formulations of drugs, allowing only one administration of active pharmaceutical ingredients with a therapeutic effect ranging from a couple of days to many months. Medincell assists pharmaceutical companies with MedinGel, its advanced polymeric drug delivery system, delivering small molecules, peptides and proteins with a better efficacy, reduced side effects and a compliance drastically improved.
TECHNOLOGY :
The MedinGel delivery platform is a sustained-release technology that delivers therapeutic levels of wide spectrum of drugs over a few days to several months with a single administration. Formulating API in the MedinGel controlled-release system has the potential to reduce its frequency of administration and contribute to lower costs and improved patient compliance. This attractive way to overcome dose administration frequency problem is to create a dosage form within a MedinGel injectable depot formulation, that delivers API in a sustained fashion, thus maintaining the API concentration within the therapeutic window for an extended period. The MedinGel delivery platform is currently facilitating the advancement of many NCEs which face challenges with their current formulations. Our dedicated team of scientists and formulators allow to accelerate product development timelines, reducing risk and increasing chances for success. The application of our MedinGel delivery platform enables also extension of the patent life for existing therapeutics, thereby securing valuable intellectual property for longer-term revenues.
OBJECTIVES :
Meet US and French biotech/Pharma companies that wish to develop best-in-class products !
COMPANY INFORMATION :

Close
Thumb_1347640834_logo-retouche-jpg

PhenoPro

visit website request a meeting with this company
PhenoPro is a CRO company dedicated to mouse model phenotyping and in vivo preclinical drug screening at the early preclinical stage.
More ?
COMPANY :
PhenoPro is a CRO company dedicated to mouse model phenotyping in the early preclinical stage, aiming to provide services to the scientific community, and more specifically to pharmaceutical and biotechnology industries. PhenoPro‘s expertise is based on the know-how from the Institut Clinique de la Souris (ICS). We perform characterization and validation of mouse mutant models to better understand the gene function and pathophysiology of diseases, as well as in vivo preclinical drug screening studies (Target identification and validation / Efficiency/ Risk assessments). PhenoPro offers services to explore a wide range of in vivo functions in physiology, behavior and cognition with more than 250 validated assays covering more than 500 different parameters: - Neurobiology and Behavior: analysis of sensory responses, motor abilities, cognitive functions, anxiety, depression, schizophrenia, pain sensitivity, epilepsy. - Cardiovascular system: analysis of ventricular dysfunctions, cardiac hypertrophy, trouble of conduction, arrhythmias, hypertension. - Respiratory function: lung inflammatory diseases and bronchial hyperreactivity, asthma models - Metabolism: analysis of the in vivo energy balance, glucose homeostasis, intestinal function, bone metabolism and renal function, under standard or challenged conditions - Clinical chemistry: large panel of measurements in blood, urine and tissue samples; various blood metabolites, ions and enzymes, endocrinology, hematology, immunology and coagulation. - Histopathology and Embryology: comprehensive histopathological analysis. PhenoPro offers a broad view of your project. Our scientific report and analysis integrate each raw data and specific result leading to a comprehensive view of your model. PhenoPro’ services are based on Standardized Operational Procedures (SOPs), quality system management and customized protocols to fit your needs and objectives.
TECHNOLOGY :
PhenoPro provides standardized, comprehensive or advanced, functional characterization of mouse models to better understand the function of genes, basic mechanisms of biology, pathophysiology of diseases, to identify and validate new drug targets and to perform risk assessment. More than 250 phenotyping assays have been validated to cover a wide range of functions: - The Neurobiology and Behavior service has developed a test battery adapted to the mouse. This includes analysis of sensory responses, motor abilities, cognitive functions and behaviors related to symptoms of neuropsychiatric disorders such as anxiety, depression and schizophrenia. Tests may be utilized as a package for phenotyping genetically modified mice or to screen for potential therapeutics. Alternatively, individual tests may be used as required. - The Cardiovascular service is designed to detect the main cardiac phenotypes: congenital cardiac disease, ventricular dysfunctions, cardiac hypertrophy and dilatation, trouble of conduction, arrhythmias, hypertension and hypotension. We also propose several pathological models to reveal phenotypes in genetically mouse models mice or to test compounds. - Different tests enable also to explore mechanisms involved in lung inflammatory diseases such as airway hyperreactivity and bronchial inflammation in order to phenotype genetically engineered mice and / or to screen in vivo potential therapeutic drugs. - The Metabolic Exploration service performs specific, on-demand experiments as well as comprehensive metabolic analysis with primary and secondary phenotypic screens to evaluate in vivo the energy balance in mouse. These screens are performed under either basal condition or energy challenges using standardized techniques for the detection of phenotype in energy metabolism, glucose homeostasis, intestinal function, bone metabolism and renal function. The platform provides users with techniques and scientific support for the design of experimental protocols as well as for the development of new techniques for the investigation of metabolism. The Metabolic Exploration service has large experience in phenotyping mouse model for diabetes, obesity and atherosclerosis. - The laboratory of clinical chemistry performs a large panel of tests in blood, urine and tissue samples. The measurement of various blood metabolites, ions and enzymes gives a screening of the major metabolic function such as water and sodium distribution, kidney, liver and gastrointestinal tract. Most of the endocrine functions can be evaluated through the measurement of several circulating hormones. Blood hematology, immunology and coagulation parameters are also performed. - The Histopathology and Embryology facility provides a comprehensive histopathological analysis of mutant or treated mice. Various histological procedures are applied to detect and analyze systematically organ defects and tissue alterations in mice at precise stages of their developmental history, and in adult and ageing mice. The facility also has the capacity to perform analysis of cell proliferation and apoptosis and immunohistochemical assays using commercialy available antibodies.
OBJECTIVES :
The objectives are to find new partnerships with companies to: - Accelerate the process of drug discovery: identification and validation of novel therapeutic targets, understanding of the in vivo mechanism of action, screening of novel drug candidates in vivo, development of customized protocols based on hundreds of assays to meet the specific needs of your research programs. - Optimize the research costs: avoid long term costs when working with imperfect models, highlighting side effects and identifying potential toxicity. - Bring an additional go / no go step in the decision tree to ensure a success of your development program.
COMPANY INFORMATION :

Close
Thumb_1347027143_logo-quinten-good-jpg

QUINTEN

visit website request a meeting with this company
Quinten is a strategy and operations consulting firm specialized in leveraging biomedical data for pharmaceutical, biotechnology and cosmetics companies.
More ?
COMPANY :
Quinten’s know-how and technology complements traditional modeling and data-mining techniques, since it enables to identify, characterize and leverage profiles of patients corresponding to best and worst practices in terms of response or resistance to a treatment, or the occurrence of adverse events.
TECHNOLOGY :
The Q-Finder® algorithm and methodology designed and developed by Quinten enable all variables to be taken into account without any preconceptions, so as to extract from any database the best and worst configurations according to predefined performance criteria. This may make it possible, for example, to utilize clinical trial data to identify and characterize the profiles of patients who respond or do not respond to a treatment. Whereas other approaches seek to identify the global model enabling the phenomenon of interest to be predicted as precisely as possible, the Q-Finder® approach involves identifying the multiple situations in which the phenomenon is produced significantly more (or less) frequently than in average. In effect, Q-Finder® makes it possible to highlight quickly the most relevant combinations of features in a database so as to detect zones of great value or high risk. The services provided by Quinten are performed in a short time frame, within six to eight weeks on average. They can span the whole drug development cycle, from early-stage research to post-commercialization studies: • Accelerating drug candidate optimization programs • Improving success rates in advanced clinical trials • Identifying new signatures of targeted biomarkers • Anticipating and preventing problems linked to drug safety • Optimizing the allocation of promotional resources Quinten always starts its assignments by a two weeks long preliminary analysis of the client’s data so as to provide an initial level of insights, validate the data’s potential in light of the client’s objectives, and identify the best learning strategy. Following the preliminary analysis phase, the data are exploited utilizing the Q-Finder® algorithm and methodology. When Quinten has finished its work, the client receives a simulation tool and a summary report containing a set of operational recommendations.
OBJECTIVES :
We are looking for executives in Pharma & Biotech companies or academic research centers, who feel the opportunity to leverage the full potential of available data to accelerate discoveries, secure ongoing developments, and reach outstanding performance.
COMPANY INFORMATION :

Close
Thumb_1348494487_logo-final-jpg

ROOWIN S.A.

visit website request a meeting with this company
Roowin is an all-in-one-package from drug discovery to phase II in CMC
More ?
COMPANY :
Roowin is focused on supporting our customers and partners to advance their drug candidates from early research phase up to licensing out API in phase II. We help our clients to develop their pharmaceutical components and to go from their ‘IDEA’ of a drug product to a launched drug product. We deliver customized services and therapeutic development programs with their essential biopharmaceuticals for all phases of your projects; hit discovery, lead optimization, creation, optimization and scale up of efficient chemical routes and analytical methods. We are dedicated to bringing our customers cutting edge pharmaceutical expertise in fine chemistry combined with innovative R&D strategy and efficient implementation. Our guarantee: handle the risk guarantee of the product whatever the problem that will occur during the project so that our clients can save time, financial and human resources.
TECHNOLOGY :
Roowin’s missions are: • Hit discovery, • Lead optimization, • Drug discovery, • Custom and NCE synthesis from mg to 50 kg, • Process development, • GMP synthesis from 1g to 50 kg, • Analysis on demand, • Development and validation of analytical method under ICH, • Stabilities and stress studies. We have developed a strong expertise in fields of: heterocycles, glycolipids, oligosaccharides, steroïds, alcaloïdes, cytotoxics and peptides synthesis. We can perform all kind of reactions (depending on the scale) plus special kind of reactions including photochemistry, microwave chemistry, nitration and very low temperature (-80°C). Roowin owns the totality of its development and production tools, made of very high-level equipment and new state-of-the-art apparatus. Roowin’s team is installed in 1500 m2 of GMP or non-GMP spaces from R&D laboratories, kilo-laboratory up to the pilot plant. Analytical and Quality Control laboratories of Roowin have a broad range of apparatus: • LC/NMR (500 Mhz) • NMR 300MHz with 60 positions auto sampler. • HPLC systems with different types of detector: UV, DAD, ELSD, Fluorimetric, Refractometric. • UPLC • QTOF • LCMS systems with Simple Quad Mass detector, Triple Quad Mass detector. • Gas Chromatographies with FID detector and Liquid/ HeadSpace injector, GC/MS. • DSC, UV spectrometer, IR.
OBJECTIVES :
We are looking for companies that have small molecules in development from hit discovery to phase II. We are interested in making a business or a partnership relationship.
COMPANY INFORMATION :
  • Address :
      20 rue Henri Goudier Z.I. La Varenne - 63200 Riom - Puy de Dôme
  • Website :
     http://www.roowin.fr

Close
Thumb_1347648821_logo-ubi-png

UBIFRANCE

visit website request a meeting with this company
Ubifrance is the French agency for international business development. Our mission is to assist French exporters in building international partnerships and exploring business opportunities.
More ?
COMPANY :
Based in New York, San Francisco and Chicago, the US Biotech Team works with more than 300 French and 500 US biotech companies each year. Our services include targeted market research, international business development assistance, identifying potential partners and organizing biotech conferences. UBIFRANCE welcomes the opportunity to help US companies and organizations in building connections with the French biotech industry. These service are free.
OBJECTIVES :
We are interested in meeting both French and American companies in the biotech industry that are seeking international licensing, partnership, or collaboration opportunities.
COMPANY INFORMATION :

Close
Thumb_1347464178_logo-web-version-jpg

VIVALIS

visit website request a meeting with this company
Discovery of native monoclonal antibodies from Human B lymphocytes
More ?
COMPANY :
VIVALIS is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines, and develops monoclonal antibodies for the prevention and treatment of unmet medical needs.
TECHNOLOGY :
Vivalis offers a cutting-edge solution for the discovery of extremely rare monoclonal antibodies, with a high therapeutic value, isolated from individual human B-lymphocytes. This technology relies on the access to a large panel of human blood donors to select those with the highest and most potent antibody response against a particular target and on an efficient, massive in vitro culture and screening of primary B-lymphocytes for the secretion of antibodies of therapeutic relevance using a high throughput single-cell microarray platform initially developed by SC World (Japan). Each micro-well-array chip can capture 250,000 lymphocytes separately at a time, in a manner of trapping them in each micro-well of the chip. The lymphocytes B are screened at a single cell level as antibody that each B cell secretes can be detected with high accuracy. Thus, the identification of extremely rare and active monoclonal antibodies across multiple indications, including oncology, CNS, inflammatory diseases is now achievable.
OBJECTIVES :
Setting up antibody discovery collaboration with new partners
COMPANY INFORMATION :

Close